Optimizing immunomodulator therapy for inflammatory bowel disease

Current Gastroenterology Reports

Volumn 5, Issue 6, 2003, Pages 506-511

  Dubinsky, Marla C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 6 METHYLTHIOINOSINE; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISONE; THIOGUANOSINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; XANTHINE OXIDASE; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT; METHYLTRANSFERASE;

ALLERGIC REACTION; ANTIINFLAMMATORY ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; CROHN DISEASE; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG INFUSION; DRUG METABOLISM; DRUG SAFETY; ENTERITIS; ENZYME ACTIVITY; ENZYME INHIBITION; FEVER; GROWTH DISORDER; HEPATITIS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; INFECTION; INFUSION SITE REACTION; LEUKEMIA; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; NAUSEA; PANCREATITIS; PHARMACOGENETICS; REMISSION; REVIEW; ULCERATIVE COLITIS; DOSE RESPONSE; METABOLISM; PHYSIOLOGY; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ADJUVANTS, IMMUNOLOGIC; AZATHIOPRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHYLTRANSFERASES; TREATMENT OUTCOME;

EID: 1542435319     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-003-0041-7     Document Type: Review

References (39)

1. Willoughby JMT, Kumar PJ, Beckett J, Dawson AM: Controlled trial of azathioprine in Crohn's disease. Lancet 1971, 731:944-947.
2. Candy S, Wright J, Gerber M, et al.: A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995, 37:674-678.
3. Present DH, Korelitz BI, Wisch N, et al.: Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double blind study. N Engl J Med 1980, 302:981-987.
4. Rosenberg JL, Wall AJ, Levin B, et al.: A controlled trial of azathioprine in the management of ulcerative colitis. Gastroenterology 1975,69:96-99.
5. Hawthorne AB, Logan RF, Hawkey CJ, et al.: Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992, 305:20-22.
6. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med 1995, 123:132-142.
7. Sandborn W, Sutherland L, Pearson D, et al.: Azathioprine or 6-mercaptopurine or inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000, 2:CD000545.
8. Steinhart AH, Ewe K, Griffiths AM: Corticosteroids for maintaining remission in ulcerative colitis. Cochrane Database of Syst Rev 2000, 2:CD000301.
9. Munkholm P, Langholz E, Davidsen M, Binder V: Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994, 35:360-362.
10. Hyams J: Corticosteroids and growth. J Pediatr 1988, 113:249-254.
11. Markowitz J, Grancher K, Kohn N, et al.: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000, 119:895-902.
12. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
13. Cohen RD, Stein R, Hanauer SB: Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999, 94:1587-1592.
14. Korelitz BI, Present DH: Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci 1985, 30:58-64.
15. Korelitz B, Hanauer S, Rutgeerts P, et al.: Post-operative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease. Gastroenterology 1998, 114:G441.
16. McGovern DP, Shobowale-Bakre E, Duley J, et al.: Early azathioprine intolerance in IBD patients is imidazole-related and independent of thiopurine methyl transferase (TPMT) activity [abstract]. Gastroenterology 2000, 118:A890.
17. Dubinsky MC, Vasiliauskas EA, Singh H, et al.: 6-Thioguanine (6-TG) can cause serious liver injury in inflammatory bowel disease (IBD) patients. Gastroenterology 2003, 125:298-303.
18. Kirschner BS: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998, 115:813-821.
19. Connell WR, Kamm MA, Ritchie JK, Lennard Jones JE: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993, 34:1081-1085.
20. Present DH, Meltzer SJ, Krumholz MP, et al.: 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989,111:641-649.
21. Lewis JD, Bilker WB, Brensinger C, et al.: Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001, 121:1080-1087.
22. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al.: Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002, 122:72-77.
23. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980, 32:651-662.
24. Lennard L, Van Loon JA, Weinshilboum RM: Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989, 46:149-154.
25. Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6 mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705-713.
26. Lennard L, Lilleyman JS: Variable 6-mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989, 7:1816-1823.
27. Lennard L, Gibson BES, Nicole T, Lilleyman JS: Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukemia. Arch Dis Child 1993, 69:577-579.
28. Regueiro M, Mardini H: Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. J Clin Gastroenterol 2002, 35:240-244.
29. Campbell S, Kingstone K, Ghosh S: Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low dose azathioprine. Aliment Pharmacol Ther 2002,16:389-398.
30. Ewe K, Press AG, Singe CC, et al.: Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993, 105:367-372.
31. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ: Baldalazide and azathioprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology, 1999, 116:1505-1506.
32. Lowry PW, Franklin CL, Weaver AL, et al.: Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001, 49:656-664.
33. McLeod HL, Relling MV, Liu Q, et al.: Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995, 85:1897-1902.
34. Dubinsky MC, Hassard PV, Seidman EG, et al.: Preliminary evidence suggests that 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122:904-915.
35. Lennard L, Rees CA, Lilleyman JS, Maddocks JL: Childhood leukemia: a relationship between intracellular 6-MP metabolites and neutropenia. Br J Clin Pharmacol 1983, 16:358-363.
36. Lennard L, Van Loon JA, Weinshilboum RM: Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989, 46:149-154.
37. Cuffari C, Théorêt Y, Latour S, Seidman EG: 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996, 39:401-406.
38. Cuffari C, Hunt S, Bayless T: Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001,48:642-646.
39. Lowry PW, Franklin CL, Weaver AL, et al.: Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001, 49:665-670.